IRE strengthens its leadership in radiopharmaceutical production with the arrival of the 30 MeV IBA cyclotron at its site

Fleurus, December 17th, 2024 – The Institute for Radioelements (IRE) announces the arrival of a 30 MeV IBA cyclotron at its Fleurus site this Tuesday, December 17th, 2024. This strategic investment marks a decisive step in IRE’s commitment to expanding its production capacities and enhancing its self-sufficiency in Germanium-68 (Ge-68) production.

Control over Ge-68 production and supply Chain

With this cyclotron installation, IRE gains increased control over its production chain, particularly concerning the supply of Germanium-68 (Ge-68). This radionuclide is the raw material for producing Gallium-68 (Ga-68) generators (Galli Eo & Galli Ad), currently used in more than 30 countries for precise medical imaging via PET cameras, especially in cancer diagnosis. Ga-68 helps detect and localize tumors, thereby guiding the most personalized treatments for patients. By mastering Ge-68 production, IRE ensures not only the continuity of its supply but also the stability and flexibility needed to meet growing demand.

Towards commercial production in 2026

IRE is following an ambitious roadmap with the cyclotron integration. Key milestones remain before the first production launch, targeted for 2026. New laboratory construction, along with validation and process implementation phases, will be completed in the coming months. These steps will enable IRE to ensure maximum quality and safety in its production.

Erich Kollegger, CEO of IRE, stated: «The arrival of the IBA cyclotron is a significant turning point in IRE's history. This project demonstrates our capacity to innovate, diversify our activities, and control the entire production chain of essential radionuclides for nuclear medicine. We are committed to meeting the growing market needs and maintaining our position as an industry leader.”

Bérénice Pignol

IRE - IRE ELiT

 

 

 

Get updates in your mailbox

By clicking "Subscribe" I confirm I have read and agree to the Privacy Policy.

About IRE and IRE ELiT

Founded in 1971 and based in Fleurus, in the province of Hainaut, the National Institute of Radioelements (IRE), a Belgian foundation of public interest, is one of the very few players worldwide capable of producing and developing certain radioisotopes used in nuclear medicine.

IRE is notably the global leader in the production of Molybdenum‑99, the “parent” isotope of metastable Technetium-99m. Using a gamma camera, this isotope makes it possible to observe a patient’s internal anatomy in real time (heart, bones, lungs, thyroid, brain, kidneys, etc.) and to diagnose certain diseases at an early stage. IRE supplies around 50% of European demand for Mo-99 and 25% of global production, a share that can rise to up to 65% during periods of global supply tension.

At the same time, IRE ELiT, a subsidiary founded in 2010, is one of the two global leaders in pharmaceutical‑grade Ge-68/Ga-68 generators for human use. Gallium-68 (Ga-68) is a key isotope for high‑precision PET imaging - particularly for neuroendocrine tumours and prostate cancer - and for personalised medicine in radioligand therapy (RLT) strategies. IRE-ELiT’s Ga-68 generators are currently marketed in around 40 countries.

Beyond its production activities aimed at improving patient care and quality of life, IRE also contributes - through its IRE Lab division - to environmental protection and monitoring. The Institute offers services for radioactivity measurement in various samples, radiological characterisation of waste and contaminated materials, as well as consultancy and technical support in the radiological and nuclear fields.

Today, IRE and IRE ELiT employ 300 people, all committed to translating cutting‑edge scientific advances into diagnostic and therapeutic solutions for patients.

More information: www.ire.eu

Contact

www.ire.eu